数据价值释放离不开标准化支撑，济南遵循国家局8类47项核心指标，新增296项本地指标，构建"钱、 效、错"三维标准化指标体系，让数据成为医保治理核心引擎。 聚焦"钱"：公开基金运行，透明化消除疑虑。聚焦基金运行，公开收支结余等32项指标，重点发布医保 基金支撑能力、收支同比增长等核心数据；创新增设医疗机构门诊费用、区域排名情况等指标，公开使 用规则，消除机构顾虑，提升基金透明度。 协同联动破壁垒，凝聚医保治理合力 医保数据高效应用需跨业务系统协同，济南医保通过机制创新打破信息壁垒，凝聚治理合力。 专班统筹强协作，畅通数据发布链路。针对指标数据分散于业务经办、支付方式、招采等多个独立系 统，数据融合治理难度大的难点，济南建立工作专班机制，明确分工、定期会商、实时共享信息，将反 复沟通转化为高效协同，提升效率的同时筑牢数据质量防线。自2024年8月组建首个医保数据工作组以 来，已形成稳定机制，累计定向发布数据报告19次(期)，逐步实现发布常态化、规范化。 协商共议搭桥梁，提升政策实操性。发挥医保数据工作组桥梁作用，吸纳14名各级医疗机构代表，覆盖 不同层级医疗主体。围绕DRG付费病组权重调整等关键议题，组织专题协 ...

Policy Developments - The National Healthcare Security Administration has established data working groups across all regions, with the aim of enhancing data governance and transparency in healthcare funding [2] Drug and Device Approvals - Jiangsu Tianshili submitted a listing application for the new drug PXT3003, intended for the treatment of Charcot-Marie-Tooth disease type 1A [4] Capital Markets - Ruijian Pharmaceutical completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [6] - Weichan Medical announced the completion of several million RMB in angel round financing, aimed at accelerating product development and market entry [7] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure the domestic supply of critical medications [8] Industry Events - Boya Bio disclosed plans to sell 80% of its subsidiary, Boya Xinha, to focus on its core blood products business, with an initial listing price of 213 million RMB [10] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [12] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [13] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [14] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [15] - People's Tongtai reported a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [16] - Haizike reported a revenue of 3.721 billion RMB for 2024, with a net profit of 395 million RMB, up 34% [17] - Hainan Haiyao reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [18] - Wantai Bio reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [19] Public Opinion Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons, effective April 11, 2025 [21] - Zhaoyan New Drug acknowledged unusual fluctuations in its stock price, linked to a recent FDA plan that may impact the industry [23]

Policy Developments - The National Healthcare Security Administration has established data working groups across all regions to enhance data governance and transparency in healthcare funding [2] - These groups will regularly publish data to improve the quality of healthcare services and ensure the safety of healthcare funds [2] Drug and Device Approvals - Jiangsu Tian Shi Li has submitted a listing application for a new drug PXT3003, aimed at treating Charcot-Marie-Tooth disease type 1A [3] Capital Markets - Ruijian Pharmaceutical has completed nearly 100 million RMB in B+ round financing, bringing total financing to over 200 million RMB in less than six months [4] - Weichan Medical has announced the completion of several million RMB in angel round financing to accelerate product development and innovation [5] - Novartis plans to invest $23 billion in the U.S. over the next five years to enhance production capabilities and ensure key drugs are manufactured domestically [6] Industry Events - Boya Biotechnology intends to sell 80% of its subsidiary, Jiangxi Boya Xinhao Pharmaceutical, to focus on its core blood products business [7] Financial Reports - Pumen Technology reported a revenue of 1.148 billion RMB for 2024, with a net profit of 345 million RMB, reflecting a 5.12% increase [8] - Huaxi Biotechnology's revenue for 2024 was 5.371 billion RMB, down 11.61%, with a net profit of 174 million RMB, down 70.59% [9] - Watson Bio reported a revenue of 2.821 billion RMB for 2024, down 31.41%, with a net profit of 142 million RMB, down 66.10% [10] - Innovation Medical reported a revenue of 816 million RMB for 2024, with a net loss of 93.95 million RMB [11] - Renmin Tongtai achieved a revenue of 10.048 billion RMB for 2024, down 3.29%, with a net profit of 213 million RMB, down 27% [12] - Haishi Pharmaceutical reported a revenue of approximately 999 million RMB for 2024, down 33%, with a net loss of 1.525 billion RMB [14] - Wantai Biological reported a revenue of approximately 2.245 billion RMB for 2024, down 59.25%, with a net profit of 106 million RMB, down 91.49% [15] - Haishi Pharmaceutical reported a net profit of 395 million RMB for 2024, up 34% [13] Public Sentiment Alerts - Xinghao Pharmaceutical announced the resignation of director Li Huiqu due to personal reasons [16] - Zhaoyan Pharmaceutical acknowledged unusual fluctuations in its stock price, linked to FDA plans that may impact the industry [17]